K1: Evaluates the information obtained using a critical sense and establishes working hypotheses. K2: It gathers knowledge in various aspects necessary for the development of professional activities. K14: Distinguishes the process of extracellular signal transmission and the types of mediators involved. K20: Describes the most frequent alterations in the structure and function of the cardiovascular system and identifies the relevant genetic and metabolic alterations in the development of tumours. K29: Describes the bases of the different oncological processes, their manifestations, diagnosis and therapeutic approaches. K41: Describes the molecular basis of the different oncological processes, their manifestations and diagnosis. S1: It uses different techniques to find, manage and integrate available digital information. S2: Prepares reports to effectively communicate project knowledge, objectives and results to specialised and non-specialised audiences. S11: Develops work skills and interpersonal relations in a work environment, using information and communication tools and techniques for data analysis and the elaboration of oral and written reports, public presentations and other training and professional activities. S12: Appropriately uses the scientific and technical vocabulary of the different fields of biomedicine and the scientific method to analyse data and design experimental strategies. C1: Participates in the activities of integrated scientific working groups C2: Use the knowledge acquired for conflict resolution, learning, teamwork and negotiation processes. C3: Accepts the role of the student as a professional learner fostering university civic co-existence C4: Demuestra un comportamiento profesional adecuado, identificando los grandes principios bioéticos.

1. Types of tumours. Benign and malignant tumours. Incidence and survival. 2. Tumour cell characteristics. Cell signalling. Cell cycle control. Angiogenesis. 3. Inactivation of senescence. Apoptosis. Invasiveness and metastasis. Tumour microenvironment. Therapeutic targets. 4. Epigenetics and cancer. Methylation. Histone modification. miRNAs. Epigenetic progenitor model. Potential clinical use. 5. Tumour genome sequencing. Mutations. Number of mutations required. Pathways with more alterations. Mutations related to metastasis. Gene expression profiles. 6. Genetic alterations in leukaemias and lymphomas. 7. Genetic alterations in the most frequent carcinomas. 8. New genetic strategies applied to cancer diagnosis and treatment. Tumour heterogeneity. Biomarkers. 9. Carcinogenesis. Embryonic stem cells (ESCs) and cancer stem cells (CSCs). Techniques for analysis of CSCs and tumour phenotype. 10. Environmental carcinogenesis. Molecular mechanisms of environmental carcinogenesis. Human carcinogens. Transplacental carcinogens. 11. Familial cancer, DNA repair and cancer predisposition syndromes. 12. Genetic strategies to identify cancer susceptibility genes. 13. New treatments for tumours with mutations in tumour predisposition genes. The concept of synthetic lethality

CLASSROOM LECTURES FACE-TO-FACE CLASSES: REDUCED (WORKSHOPS, SEMINARS, CASE STUDIES) STUDENT INDIVIDUAL WORK LABORATORY SESSION FINAL EXAM SEMINARS AND LECTURES SUPPORTED BY COMPUTER AND AUDIOVISUAL AIDS. PRACTICAL LEARNING BASED ON CASES AND PROBLEMS, AND EXERCISE RESOLUTION. INDIVIDUAL AND GROUP OR COOPERATIVE WORK WITH THE OPTION OF ORAL OR WRITTEN PRESENTATION. INDIVIDUAL AND GROUP TUTORIALS TO RESOLVE DOUBTS AND QUERIES ABOUT THE SUBJECT. INTERNSHIPS AND DIRECTED LABORATORY ACTIVITIES.